Company Tyme Technologies, Inc.

Tyme Technologies, Inc. is a biotechnology company. The Company is developing cancer metabolism-based therapies (CMBTs ) that are effective across a broad range of solid tumors and hematologic cancers. It is focused on developing its novel compound, SM-88 and its preclinical pipeline of novel CMBT programs. SM-88 is an oral investigational modified proprietary tyrosine derivative that is hypothesized to interrupt the metabolic processes of cancer cells by breaking down the cells? key defenses and leading to cell death through oxidative stress and exposure to the body's natural immune system. Its therapeutic approach is designed to take advantage of a cancer cells innate metabolic weaknesses to cause cancer cell death.

Number of employees: 13